# Novo Nordisk (NVO) — InvestMoat Analysis

_Last analyzed: August 3, 2026_
_Asset class: equity · Canonical page: https://investmoat.com/stocks/nvo_

## Scores

| Dimension | Score (0–100) |
| --- | --- |
| Moat durability | 61 |
| Growth trajectory | 49 |
| Valuation | 78 |
| **Composite** | **61** |
| **Recommendation** | **Speculative Buy** |

Scores are computed deterministically from this asset’s data by the InvestMoat formula (see https://investmoat.com/llms.txt for methodology). Scores are not directly comparable across asset classes.

## Key stats

- **Ticker:** NVO
- **Market Cap:** ~$211B

## Moat

Century-old peptide manufacturing scale and a deep semaglutide regulatory estate remain real — but Lilly's tirzepatide now holds ~60% of the US GLP-1 market, CagriSema failed head-to-head non-inferiority, and announced 2027 WAC cuts lock in a multi-year price reset. The moat is durable manufacturing and approvals, not pricing power or product superiority.

### The Peptide Manufacturing Moat

Novo's moat is built on **century-old peptide manufacturing depth and the semaglutide IP estate** — still hard to replicate, but no longer translating into share leadership:

- **Peptide Manufacturing Scale:** Novo has invested tens of billions in peptide and GLP-1 manufacturing capacity globally — Catalent, Kalundborg, and Bloomington fill-finish. New entrants still face multi-year capacity build cycles. This remains the dominant practical moat, even as Lilly has closed the supply gap and now leads on US share.
- **Semaglutide Franchise + Oral Form Factor:** Ozempic, Wegovy (injectable + pill), and Rybelsus carry a deep clinical and regulatory data base. The Wegovy pill (oral semaglutide 25 mg), launched January 5 2026, posted 1.3M Q1 prescriptions and won EU marketing authorisation in July 2026 — expanding the addressable patient pool beyond injection-tolerant users. Patent expiry in major markets still clusters around 2032–33.
- **Competitive and Pricing Erosion vs Lilly:** Tirzepatide (Mounjaro, Zepbound) holds clinical efficacy leadership, and Lilly commands ~60% of the combined US GLP-1 market. CagriSema failed non-inferiority vs tirzepatide in REDEFINE 4 (23.0% vs 25.5% weight loss). On top of share loss, Novo has locked in a January 2027 WAC cut of roughly 50% on Wegovy and 35% on Ozempic — converting volume growth into revenue contraction through at least 2027.

**Moat verdict:** Novo's moat is regulatory-and-manufacturing rather than data-and-network, which makes it AI-neutral — neither helped nor materially threatened by AI. The franchise question is competitive versus Lilly and the depth of the 2027 price reset, not technological obsolescence. Current valuation prices in continued share loss and a trough earnings year; manufacturing scale and the oral form-factor are the residual upside, not a restored product-superiority narrative.

## Growth

Q1 2026 adjusted sales fell 4% CER to DKK 70.1B (reported +32% was a USD 4.2B 340B provision reversal). Obesity care rose 22% CER on Wegovy volume — injectable +12% CER, pill DKK 2.3B in its debut quarter — while diabetes care fell 12% CER as Ozempic (−8% CER) and Rybelsus (−15% CER) absorbed lower realised prices. FY2026 adjusted sales and operating profit are guided −4% to −12% CER. The January 2027 WAC reset (~50% Wegovy / ~35% Ozempic) extends the price trough into FY2027; 3–5 year growth depends on whether oral volume and international launches outrun that reset. ZEUS (ziltivekimab) failed its MACE primary endpoint on July 31 — a diversification setback that does not change the 2026 profit guide but removes a CV pipeline option.

- **Revenue CAGR estimate:** 1–5%
- **Primary type:** TAM expansion
- **Margin trend:** compressing
- **Key risk (moderate):** If amycretin (zenagamtide) Phase 3 weight-loss data in 2027–28 fails to clear a clinically meaningful bar versus Lilly's retatrutide (~28.7% in TRIUMPH-4), and Wegovy pill weekly TRx falls below 150k as the Q1 pipeline-fill anniversary comps, Novo's 2028–29 revenue recovers into a mid-single-digit ceiling and the multiple stays pinned near the global-pharma 12–13× median.
- **Drivers:**
  - Wegovy oral + HD — Pill: 1.3M Q1 TRx / DKK 2.3B sales; HD 7.2 mg FDA-approved March, 20.7% mean WL in STEP UP; EU pill authorised July 2026 (accelerating)
  - Ozempic / diabetes GLP-1 — Ozempic −8% CER, Rybelsus −15% CER in Q1; diabetes care −12% CER on realised-price pressure (decelerating)
  - International Operations — +6% CER in Q1 on volume; Wegovy in 55+ countries; first ex-US pill launches H2 2026 (stable)
- **Score derivation:** Base ~58 (1–5% CAGR midpoint after charging FY26 decline and 2027 WAC cuts into the estimate) + 0 trajectory (oral accelerating offset by diabetes decelerating) − 4 compressing margins (adj. gross margin 80.6% vs prior-year 83.5%; further WAC step-down ahead) − 5 moderate residual risk (amycretin differentiation still open) ≈ 49. Share loss to Lilly and CagriSema's REDEFINE 4 miss are already in the CAGR base, not double-counted in severity.

## Valuation

At ~$47 — after the July 31 ZEUS miss cut the stock ~9% in a day — NVO trades at ~11× trailing GAAP and ~14–17× forward EPS with a ~3.7% dividend yield, a deep discount to Lilly (~30×+) and to Novo's own 5-year median (~24×). The discount correctly prices a multi-year price reset and share loss; the question is whether oral volume plus manufacturing scale can restore mid-teens EPS growth off the 2027 trough. Near the middle of the bear-to-base corridor, risk/reward is balanced rather than asymmetric.

| Multiple | Value | Note |
| --- | --- | --- |
| Trailing P/E (GAAP) | ~11× | TTM EPS ~$4.20; 340B reversal inflates |
| Forward P/E (NTM) | ~15× | consensus EPS est. ~$3.20–3.40 |
| PEG Ratio | ~5× | fwd P/E ÷ ~3% EPS CAGR |
| Price / Sales (NTM) | ~4.5× | vs LLY ~13×; GPharma ~3× |
| Price / FCF | ~20× | FY26 FCF guide DKK 36–46B |

Forward P/E in the mid-teens is cheap versus Lilly and versus Novo's history, but fair-to-expensive versus a 1–5% revenue CAGR — the PEG near 5× says the multiple still embeds more growth than the price-reset path currently supports. The trailing-to-forward gap (11× → 15×) is a deceleration signal: 2026–27 earnings are stepping down, not ramping. _(as of August 2026)_

## Price scenarios

### Bear — $34

Amycretin disappoints, oral Wegovy comps fade after pipeline fill, Lilly share exceeds 65%, and the multiple compresses to ~10× on trough EPS as the 2027 WAC cut fully flows through.

- Amycretin Phase 3 weight loss fails to differentiate vs retatrutide; CagriSema FDA decision is a non-event after REDEFINE 4
- Wegovy pill weekly TRx falls below 150k as Q1 2026 pipeline-fill anniversary comps hit in early 2027
- US GLP-1 share drifts below 35% and Medicare/MFN pricing compounds the January 2027 WAC cut

### Base — $62

Oral Wegovy sustains >200k weekly TRx into 2027, share stabilises near 35–40%, amycretin Phase 3 is competitive enough to keep the franchise credible, and the multiple holds ~17× on recovering 2028 EPS.

- GLP-1 market share stabilises around 35–40% Novo / 60–65% Lilly through 2028
- Ex-US Wegovy pill launches in H2 2026–2027 add a second volume engine after the US WAC reset
- Zenagamtide AMAZE Phase 3 data in 2027–28 clears a commercially useful bar even if short of retatrutide

### Bull — $92

Amycretin posts Phase 3 weight loss competitive with retatrutide, oral form-factor expands the treated population faster than price cuts destroy revenue, and the multiple re-rates toward ~22× as the franchise quality is reassessed.

- Amycretin Phase 3 demonstrates differentiation that restores a next-gen injectable/oral narrative vs Lilly
- Wegovy pill + HD volume drives obesity-care revenue back to double-digit growth by 2028 despite the WAC reset
- Multiple re-rates to ~20–22× as investors price manufacturing scale and oral category leadership

---

InvestMoat is an open-source research and education framework. Nothing here is financial advice. Past performance does not guarantee future results.